Fig. 2.

Mean change from baseline in serum potassium levels in patients at increased risk of hyperkalemia. Patients receiving a ACE inhibitors or ARBs and b potassium-sparing diuretics in the pooled population (study duration ≤24 weeks); c patients with moderate renal impairment [30] (study duration 52 weeks). Asterisks number of treated patients with non-missing values at baseline and at that study week. ACE angiotensin-converting enzyme, ARBs angiotensin receptor blockers, BL baseline, CI confidence interval, DAPA dapagliflozin, SD standard deviation